1. Scrip
  2. >>R&D

GeNeuro To Tackle Long COVID By Targeting Ancestor Viral Gene Activation

Will Assess Its HERVs MAb Temelimab in Covid-19 Patients

 
• By Sten Stovall

Switzerland’s GeNeuro will study whether its monoclonal antibody temelimab can prevent long-COVID, after data for the first time linked activation of human endogenous retroviruses (HERVs) to the condition and its associated neurological symptoms.

HERV-W ENV was found in COVID-19 Patients and Linked to Disease Severity • Source: Alamy

Swiss biotech GeNeuro SA is to test its investigational lead asset temelimab in COVID-19 patients, encouraged by new data suggesting that infection could activate the pathogenic envelope protein of the human endogenous retrovirus W (HERV-W ENV).

It seems there is a genetic and/or epigenetic susceptibility to severe COVID-19 tied to activation of the pro-inflammatory HERV-W ENV protein in blood lymphoid cells, a finding that could help in understanding how SARS-CoV-2 infection may lead to severe disease in some patients

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D